Concord Biotech Limited — Important, 11-11-2024: Financial Result Updates

Concord Biotech Limited's Board approved unaudited financial results for Q2 and the half-year ended September 30, 2024. Revenue from operations reached ₹31,018.12 lakhs, with a profit after tax of ₹9,869.94 lakhs. The company reported total comprehensive income of ₹9,846.91 lakhs, reflecting robust performance and growth compared to the previous year. The financial results have been reviewed by the Audit Committee and the statutory auditors.